WaferGen's Q4 Revenues Rise Sharply | GenomeWeb

NEW YORK (GenomeWeb News) – WaferGen Biosystems reported that its fourth-quarter revenues increased more than 700 percent year over year as sales of its PCR products grew.

In its Form 10-K filed with the US Securities and Exchange Commission on Friday, the Fremont, Calif.-based firm provided limited information about its fourth-quarter financials, saying revenues increased to $316,177 from $37,906 a year ago.

Its net loss for the quarter, it added, was $1.0 million, or $.03 per share, compared to a net loss of $3.7 million, or $.09 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.